Posts by Mark Clapp, MD
-
Review: Achieving Equity in Telemedicine in Obstetrics
Allison S. Bryant, MD, MPH, and Mark A. Clapp, MD, MPH, note that while lack of broadband access is a key impediment to telehealth, clinicians can address other barriers, including patient dissatisfaction, distrust, and fears, that are greater in certain communities and patient populations than others.
-
Using Artificial Intelligence to Decrease Obstetric Risk
Physicians at Massachusetts General Hospital are researching how artificial intelligence methods in obstetrics can help to identify high-risk patients and optimize labor and delivery outcomes.
-
Natural Language Processing of Admission Notes at Delivery Predicts Severe Maternal Morbidity
Mark A. Clapp, MD, MPH, a Maternal–Fetal Medicine Program specialist, and colleagues created a computer algorithm to predict severe maternal morbidity simply by reviewing the free-text history and physical notes in the patient's chart at the time of hospital admission for delivery.
-
Risk Score for Maternal Morbidity Can Also Predict Postpartum Hemorrhage
Maternal-fetal medicine specialists at Massachusetts General Hospital found that the Expanded Obstetric Comorbidity Score (EOCS), a risk-stratification tool recently developed for predicting severe maternal morbidity, can also be used to predict which women in labor are at risk of postpartum hemorrhage.
-
Prenatal Diagnosis Codes Predict Maternal Morbidity, Aid in Risk Stratification
Mark A. Clapp, MD, MPH, Roy H. Perlis, MD, and colleagues demonstrated the potential utility of prenatal ICD-10 codes to identify a group of women who were more than 2 to 3.5 times more likely than others to have severe maternal morbidity.
-
Failed Induction of Labor Is Infrequent According to Contemporary Standardized Definition
Mark Clapp, MD, MPH, and colleagues in the Department of Obstetrics and Gynecology found that failed induction of labor is infrequent when defined based on Obstetric Care Consensus criteria—it occurs in just 2% of inductions of labor among nulliparous women with singleton full-term or late-term gestations.
-
Outpatient Expectant Management of Term PROM Has Mixed Results
Outpatient expectant management of prelabor rupture of membranes (PROM) at term is associated with longer intervals between PROM and delivery, but shorter intervals between admission and delivery.
-
Time to Delivery After PROM at Term Is Shorter with Oxytocin than Buccal Misoprostol
Among nulliparous women presenting with prelabor rupture of membranes at term and unfavorable cervical dilation, oxytocin was associated with a significantly shorter admission-to-delivery interval and fewer vaginal exams compared with buccal misoprostol.
-
Medicaid Expansions Improved Preconception Coverage for Low-income Women
Following the passage of the Affordable Care Act, the Medicaid expansions supported by the federal government were associated with significant increases in preconception insurance coverage for low-income women, according to a study by obstetrician–gynecologists and health policy analysts at Mass General.
Biography
Dr. Clapp completed medical school at the University of North Carolina, his master of public health at Harvard University, and residency in obstetrics and gynecology at Brigham and Women’s Hospital and Massachusetts General Hospital. He currently is a maternal-fetal medicine fellow at Massachusetts General Hospital and has a research interest in quality and safety and the implications of health policies on maternity care. His recent work has focused the effects of insurance coverage changes on women’s access to maternity care and the application of the Levels of Maternal Care hospital designation system. Dr. Clapp is currently exploring novels uses of electronic health record data for accurate risk prediction in obstetrics, which is focused on reducing severe maternal morbidity and mortality.
Obstetrics & Gynecology Care at Mass General
The Mass General Department of Obstetrics & Gynecology offers the highest level of care to women. Our clinical and research team is a leader in advancing treatments for gynecologic cancers, menopause, high-risk obstetrics, infertility and urogynecology.